PALO ALTO, Calif.

加利福尼亚州帕洛阿尔托

,

，

May 1, 2025

2025年5月1日

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq:

/PRNewswire/ -- Kodiak Sciences Inc.（纳斯达克：

KOD

代码

), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that seven scientific presentations on its research programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, being held from May 4-8 in Salt Lake City, .

），一家致力于研究、开发和商业化治疗高发性视网膜疾病的变革性疗法的生物制药公司，今天宣布其研究项目将有七项科学报告在 2025 年 5 月 4 日至 8 日于盐湖城举行的视觉与眼科研究协会 (ARVO) 年会上展示。

Utah

犹他州

.

。

'We are pleased to share new data from Kodiak's research and development efforts at this year's ARVO meeting. This body of work further highlights the power and versatility of Kodiak's ABC

“我们很高兴在今年的ARVO会议上分享Kodiak研发工作的新数据。这些研究成果进一步突显了Kodiak的ABC技术的力量和多功能性。

®

®

(Antibody Biopolymer Conjugate) platform for the design and development of new medicines for complex multifactorial diseases with a high unmet need,' said Dr.

(Antibody Biopolymer Conjugate) 平台，用于设计和开发针对复杂多因素疾病的新药，这些疾病具有高度未满足的需求，”博士说道。

Victor Perlroth

维克多·佩尔罗斯

, MD and Chief Executive Officer.

医学博士，首席执行官。

'Our bispecific protein platform, the basis for KSI-101 currently in clinical development for macular edema secondary to inflammation (MESI), is fueling two new research programs in two new therapeutic categories: ocular inflammatory disease and geographic atrophy. We also present new data from our ABC.

“我们的双特异性蛋白平台，是目前正处于临床开发阶段的KSI-101的基础，用于治疗继发于炎症的黄斑水肿（MESI），这一平台正在推动两个新的研究项目，涉及两个新的治疗领域：眼部炎症疾病和地理性萎缩。我们还展示了来自我们ABC的新数据。

®

®

platform extension in which we embed diverse therapeutic payloads, such as oligonucleotides and peptides, into the biopolymer backbone at a high drug-antibody ratio (DAR) and deliver these payloads into targeted cells. We believe this is a promising strategy to power a next generation of targeted, high-DAR, multi-specific and multi-modality therapeutic candidates with relevance for retinal and systemic diseases.'.

我们嵌入多种治疗载荷（例如寡核苷酸和肽）到生物聚合物骨架中的平台扩展技术，实现了高药物抗体比（DAR），并将这些载荷递送到靶细胞内。我们认为，这是一种有前景的策略，可为下一代针对视网膜和系统性疾病的高DAR、多特异性及多模式治疗候选药物提供支持。

The seven poster presentations are listed below, grouped by topic. The posters will also be made available under Kodiak's 'Scientific Presentations' page on kodiak.com.

以下是七个海报展示的列表，按主题分组。这些海报还将在kodiak.com的Kodiak“科学展示”页面上提供。

Ocular Inflammatory Disease

眼炎症性疾病

Ocular inflammatory disease, often called uveitis, is the fourth leading cause of vision loss for working aged adults in the developed world. One-third of patients with

眼部炎症疾病，常被称为葡萄膜炎，是发达国家工作年龄成年人视力丧失的第四大原因。三分之一的患者

ocular inflammation develop macular edema, which is the leading cause of vision loss among patients with ocular inflammation. Steroids remain the mainstay treatment but can cause significant and permanent ocular adverse effects especially with long-term use or high doses. This body of work demonstrates Kodiak's strong protein engineering expertise to design innovative therapies, including KSI-101 (currently in Phase .

眼部炎症会发展为黄斑水肿，这是眼部炎症患者视力丧失的主要原因。类固醇仍然是主要的治疗方法，但长期使用或高剂量可能会导致显著且永久的眼部不良反应。这项工作展示了Kodiak强大的蛋白质工程专业知识，用于设计创新疗法，包括目前处于Phase阶段的KSI-101。

1b

1b

) and KSI-102, by targeting the underlying and complex cytokine interactions underlying chronic inflammatory ocular diseases.

）以及KSI-102，通过针对慢性炎症性眼病中复杂的基本细胞因子相互作用。

1. Title: Development of Anti-inflammatory Bispecific anti-TNF-

1. 标题：抗炎双特异性抗TNF的开发

α VHH anti-IL-6 Antibody Fusion for the Treatment of Inflammatory Retinal Diseases

α VHH抗IL-6抗体融合蛋白用于治疗炎症性视网膜疾病

Session Title: Anti-inflammatory agents, ocular toxicity, cytokines and growth factors

会议标题：抗炎药、眼部毒性、细胞因子与生长因子

Presentation Date and Time:

演示日期和时间：

May 4, 2025

2025年5月4日

; 8:00 –

；8:00 –

9:45 AM (MT)

上午9点45分（山地时间）

Presentation Type: Poster Session

报告类型：海报展示环节

Poster Number: 195-A0416

海报编号：195-A0416

Elevated levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) play distinct yet complementary roles in driving inflammatory retinal diseases such as non-infectious uveitis. Treatments targeting these cytokines individually may fail to control inflammation in a comprehensive manner.

肿瘤坏死因子-α（TNF-α）和白细胞介素-6（IL-6）等促炎性细胞因子水平升高，在非感染性葡萄膜炎等炎症性视网膜疾病的发病中发挥着独特但互补的作用。针对这些细胞因子的单独治疗可能无法全面控制炎症。

Here we present preclinical data of KSI-102, a novel bispecific antibody that potently inhibits both TNF-α and IL-6 simultaneously, offering enhanced therapeutic potential for inflammatory ocular diseases..

这里我们展示了KSI-102的临床前数据，KSI-102是一种新型双特异性抗体，能够同时有效抑制TNF-α和IL-6，为炎性眼病提供了增强的治疗潜力。

2. Title: Preserving Endothelial Barrier Function with Novel Bispecific Anti-Inflammatory Agents for the Treatment of Retinal Inflammatory Diseases

2. 标题：使用新型双特异性抗炎剂保护内皮屏障功能以治疗视网膜炎症性疾病

Session Title: Anti-inflammatory agents, ocular toxicity, cytokines and growth factors

会议标题：抗炎药、眼部毒性、细胞因子与生长因子

Presentation Date and Time:

演示日期和时间：

May 4, 2025

2025年5月4日

; 8:00 –

；8:00 –

9:45 AM (MT)

上午9点45分（MT）

Presentation Type: Poster Session

展示类型：海报展示环节

Poster Number: 196-A0417

海报编号：196-A0417

Inflammation contributes to ocular disease by triggering a cascade of pathological events, including disruption of the blood-retinal-barrier and recruitment of immune cells to retinal tissues. These processes can lead to edema and tissue damage, which are hallmark features of conditions such as macular edema and uveitis.

炎症通过触发一系列病理事件来促成眼部疾病，包括破坏血视网膜屏障和免疫细胞向视网膜组织的募集。这些过程会导致水肿和组织损伤，这是黄斑水肿和葡萄膜炎等疾病的标志性特征。

Adalimumab is an anti-TNF-α biologic approved as a steroid-sparing agent for the treatment of non-infectious uveitis (NIU). However, more than 50% of patients with NIU experienced treatment failure over 85 weeks in the VISUAL I trial. This preclinical presentation demonstrates that Kodiak's anti-TNF-α, anti-IL-6 fusion protein normalizes human endothelial morphology and junctional proteins better than monotherapy agents..

阿达木单抗是一种抗TNF-α生物制剂，被批准作为类固醇节省剂用于治疗非感染性葡萄膜炎（NIU）。然而，在VISUAL I试验中，超过50%的NIU患者在85周内治疗失败。该临床前研究表明，Kodiak公司的抗TNF-α、抗IL-6融合蛋白在恢复人体内皮细胞形态和连接蛋白方面优于单一疗法药物。

3. Title: Ocular Toxicity Study of KSI-101 Demonstrates Tolerability after Intravitreal Administration in Cynomolgus Monkeys

3. 标题：KSI-101眼毒性研究显示在食蟹猴玻璃体内注射后具有耐受性

Session Title: Retina/RPE: New drugs, mechanisms of action, and toxicity

会议标题：视网膜/视网膜色素上皮：新药、作用机制与毒性

Presentation Date and Time:

演示日期和时间：

May 8, 2025

2025年5月8日

;

；

11:45 AM

上午11点45分

–

–

1:30 PM (MT)

下午1:30（山地时间）

Presentation Type: Poster Session

报告类型：海报展示

Poster Number: 5998-A0183

海报编号：5998-A0183

KSI-101 is a first-in-class, local, high-strength bispecific protein in clinical development for the treatment of macular edema secondary to inflammation (MESI). Early clinical data of KSI-101 in the Phase

KSI-101是一种首创的局部高强双特异性蛋白，目前正处于治疗继发于炎症（MESI）的黄斑水肿的临床开发阶段。KSI-101在早期临床试验中的数据表明

1b

1b

APEX study, which is enrolling patients with MESI, demonstrates that at all dose levels, KSI-101 rapidly normalizes macular edema and improves vision. To inform and support further clinical development of KSI-101, which has demonstrated a positive safety profile in patients, here we demonstrate that repeated bilateral intravitreal administration of KSI-101 in non-human primates was safe and well tolerated..

APEX 研究正在招募患有MESI的患者，研究表明，在所有剂量水平下，KSI-101能迅速使黄斑水肿正常化并改善视力。为了进一步推动已展现积极安全性的KSI-101的临床开发，我们在此证明，在非人类灵长类动物中重复进行双侧玻璃体内注射KSI-101是安全且耐受性良好的。

The following poster was developed in collaboration with

以下海报是与

Chang Gung

长庚

Memorial Hospital, Department of Ophthalmology:

纪念医院，眼科部：

4. Title: Systemic Review of Uveitic Macular Edema (UME) Outcomes in Children Versus Adults

4. 标题：儿童与成人葡萄膜炎性黄斑水肿（UME）结局的系统评价

Session Title: Uveitis Epidemiology and Clinical Characterization

会议标题：葡萄膜炎流行病学与临床特征

Presentation Date and Time:

演示日期和时间：

May 6, 2025

2025年5月6日

;

；

8:30-10:15 AM (MT)

上午8:30-10:15（MT）

Presentation Type: Poster Session

演示类型：海报展示

Poster Number: 2849-A0142

海报编号：2849-A0142

Macular edema secondary to inflammation affects adults and children, with differing underlying causes, inflammation patterns and clinical presentations. Treatment options vary by etiology, and steroids are generally avoided in children due to serious adverse effects. This study highlights the serious impact UME in particular has on vision, especially in children, and underscores the critical need for dedicated research and the development of safe and effective therapies tailored for pediatric UME..

炎症引起的黄斑水肿影响成人和儿童，其根本原因、炎症模式和临床表现各不相同。治疗方案因病因而异，通常由于严重的不良反应，儿童避免使用类固醇。本研究强调了黄斑水肿（尤其是儿童）对视力的严重影响，并突显了针对儿童黄斑水肿开展专门研究以及开发安全有效疗法的迫切需求。

Geographic Atrophy

地理性萎缩

Geographic atrophy (GA), the advanced form of dry age-related macular degeneration, affects approximately one million patients in the U.S. and is characterized by atrophic lesions in the retina that progressively expand to the central macular and fovea, leading to irreversible vision loss. Currently there are two approved therapies for GA, both are anti-complement therapies that offer modest therapeutic benefit and require monthly or every other month intravitreal injections..

地理性萎缩（GA）是干性年龄相关性黄斑变性的晚期形式，影响美国约一百万患者，其特征为视网膜中出现萎缩性病变，并逐渐扩展至中央黄斑和中央凹，导致不可逆的视力丧失。目前有两种获批的GA疗法，均为抗补体疗法，仅提供适度的治疗效果，且需要每月或隔月进行玻璃体内注射。

5. Title: Development of Potent Bispecific Inhibitors Targeting Complement Activation and Cytokines for the Treatment of Geographic Atrophy (GA)

5. 标题：开发针对补体激活和细胞因子的强效双特异性抑制剂用于治疗地理萎缩（GA）

Session Title: New drugs, delivery systems, and mechanisms of action II

会议标题：新药、递送系统及作用机制 II

Presentation Date and Time:

演示日期和时间：

May 7, 2025

2025年5月7日

;

；

10:15 AM

上午10点15分

–

–

12:00 PM (MT)

中午12:00（山地时间）

Presentation Type: Poster Session

展示类型：海报展示环节

Poster Number: 4337-A0493

海报编号：4337-A0493

Here we present new data on a promising therapeutic strategy to treat GA by combining complement regulators with an anti-VEGF antibody to prevent wet AMD conversion and anti-IL-6 antibody to further reduce GA progression, to achieve potent concurrent inhibition of complement pathway activation and VEGF pathway signaling..

在此，我们提出了一种有前景的治疗策略的新数据，通过将补体调节剂与抗VEGF抗体结合使用，以防止湿性AMD转化，并结合抗IL-6抗体以进一步减缓GA进展，从而实现对补体通路激活和VEGF通路信号传导的有效同步抑制。

Enhancing Therapeutic Efficacy with the ABCD Platform

利用ABCD平台提高治疗效果

Antibody Drug Conjugates (ADCs) and Antibody Oligonucleotide Conjugates (AOCs) are promising platforms for targeted drug delivery but have a limited drug-antibody ratio (DAR), which poses significant challenges in optimizing therapeutic efficacy. Kodiak's Antibody Biopolymer Conjugate Drug (ABCD) platform addresses this limitation by utilizing a customizable biopolymer to enable the design and development of multifunctional, high DAR therapeutics for ophthalmic and systemic applications..

抗体药物偶联物（ADC）和抗体寡核苷酸偶联物（AOC）是靶向药物递送的有前景的平台，但其药物抗体比（DAR）有限，这在优化治疗效果方面带来了重大挑战。Kodiak的抗体生物聚合物偶联药物（ABCD）平台通过使用可定制的生物聚合物解决了这一限制，能够设计和开发多功能、高DAR的治疗药物，用于眼科和全身应用。

6.

6.

Title: Delivery of Therapeutic Oligonucleotides by Antibody Biopolymer Conjugates (ABC

标题：通过抗体生物聚合物偶联物（ABC）递送治疗性寡核苷酸

®

®

)

)

Session Title: New drugs, delivery systems, and mechanisms of action II

会议标题：新药、递送系统和作用机制 II

Presentation Date and Time: May 7, 2025;

展示日期和时间：2025年5月7日；

10:15 AM

上午10点15分

– 12:00 PM (MT)

– 中午12:00（MT）

Presentation Type: Poster Session

演示类型：海报展示

Poster Number: 4334-A0490

海报编号：4334-A0490

Here we demonstrate the intracellular drug delivery capability and target knockdown potency of Antibody Biopolymer Conjugate Oligonucleotides (ABCO) in the target cells, providing a proof of concept for ABC

在这里，我们展示了抗体生物聚合物缀合寡核苷酸（ABCO）在靶细胞中的细胞内药物递送能力和靶标敲低效力，为ABCO提供了概念验证。

®

®

mediated intracellular delivery of oligonucleotide therapeutics. We demonstrate that (a) anti-TfR1 ABCO maintains high binding affinity to TfR1, (b) the antibody and its conjugates exhibit concentration dependent uptake in HepG2 cells, enabling delivery of RNA payloads, and (c) anti-TfR1 ABCOs with siRNA or ASO effectively modulate target gene expression..

介导寡核苷酸治疗剂的细胞内递送。我们证明 (a) 抗TfR1 ABCO对TfR1保持高亲和力，(b) 该抗体及其偶联物在HepG2细胞中表现出浓度依赖性摄取，能够递送RNA负载，以及 (c) 带有siRNA或ASO的抗TfR1 ABCO有效调控目标基因表达。

7.

7.

Title: Effect of Polymer Architecture on Properties of Antibody Biopolymer Conjugates

标题：聚合物结构对抗体生物聚合物结合物特性的影响

Session Title: New drugs, delivery systems, and mechanisms of action II

会议标题：新药、递送系统及作用机制 II

Presentation Date and Time: May 7, 2025;

演示日期和时间：2025年5月7日；

10:15 AM

上午10点15分

– 12:00 PM (MT)

– 中午12:00（山地时间）

Presentation Type: Poster Session

报告类型：海报展示环节

Poster Number: 4325-A0481

海报编号：4325-A0481

This study demonstrates how polymer architecture, specifically molar mass and number of arms in homopolymers, influences conjugate properties and explores the role of structural design. These findings guide optimization and further development of biopolymer conjugated therapeutic candidates with Kodiak's ABCD platform..

本研究展示了聚合物结构，特别是均聚物的摩尔质量和臂数，如何影响共轭物的性质，并探讨了结构设计的作用。这些发现为利用Kodiak的ABCD平台优化和进一步开发生物聚合物共轭治疗候选药物提供了指导。

About Kodiak Sciences Inc.

关于 Kodiak Sciences Inc.

Kodiak Sciences (Nasdaq:

Kodiak Sciences (纳斯达克:

KOD

代码

) is a biopharmaceutical company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally.

）是一家致力于研究、开发和商业化治疗各种视网膜疾病的变革性疗法的生物制药公司。我们专注于将新科学应用于下一代视网膜药物的设计与制造，以预防和治疗全球范围内导致失明的主要原因。

Our ABC Platform.

我们的ABC平台。

®

®

uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine. We are developing a portfolio of three clinical programs, two of which are late-stage today and derived from our ABC Platform and one which is platform-independent and which we believe can progress rapidly into pivotal studies. .

利用分子工程将基于蛋白质和基于化学的治疗领域融合在一起，一直是Kodiak发现引擎的核心。我们正在开发一个包含三个临床项目的组合，其中两个目前已进入后期阶段，源自我们的ABC平台，另一个则不依赖于平台，我们认为它可以迅速推进到关键性研究。

Kodiak's lead investigational medicine, tarcocimab, is a novel anti-VEGF antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases. Tarcocimab is currently being studied in two Phase 3 clinical trials, GLOW2 in patients with diabetic retinopathy and DAYBREAK in patients with wet AMD.

Kodiak的主要研究药物tarcocimab是一种新型抗VEGF抗体生物聚合物偶联物，正在开发用于治疗高发性视网膜血管疾病。Tarcocimab目前正在两项III期临床试验中进行研究，分别是针对糖尿病视网膜病变患者的GLOW2试验和针对湿性AMD患者的DAYBREAK试验。

GLOW2 enrollment is complete, and DAYBREAK is actively enrolling patients..

GLOW2的注册已经完成，DAYBREAK正在积极招募患者。

KSI-501 is our second investigational medicine, a first-in-class anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate designed to inhibit both IL-6 mediated inflammation and VEGF-mediated angiogenesis and vascular permeability. KSI-501 is being developed for the treatment of high prevalence retinal vascular diseases to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.

KSI-501是我们第二个研究性药物，是一种首创的抗IL-6、VEGF捕获双特异性抗体生物聚合物偶联物，旨在抑制IL-6介导的炎症和VEGF介导的血管生成及血管通透性。KSI-501正在被开发用于治疗高患病率的视网膜血管疾病，以满足延长耐久性和针对超越VEGF的疾病生物学机制以实现差异化疗效的未满足需求。

The Phase 3 DAYBREAK study of KSI-501 in wet AMD is actively enrolling patients. .

KSI-501在湿性AMD的III期DAYBREAK研究正在积极招募患者。

KSI-101, our third product candidate, is a novel anti-IL-6, VEGF-trap bispecific protein. Kodiak is developing KSI-101 for the treatment of retinal inflammatory diseases, as currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina.

KSI-101是我们第三个候选产品，是一种新型的抗IL-6、VEGF捕获双特异性蛋白。Kodiak公司正在开发KSI-101用于治疗视网膜炎症性疾病，因为目前尚无可用的玻璃体内生物疗法能够针对视网膜炎症的整个范围。

The Phase .

阶段。

1b

1b

APEX study of KSI-101 is actively enrolling patients, as a precursor to activating the Phase

KSI-101的APEX研究正在积极招募患者，作为启动第3阶段的前奏。

2b

2b

/3 PEAK and PINNACLE studies in patients with macular edema secondary to inflammation ('MESI').

/3 针对炎症性黄斑水肿（'MESI'）患者的PEAK和PINNACLE研究。

Kodiak is advancing its platform technology to embed small molecules and other active pharmaceutical ingredients ('APIs') into Kodiak's proprietary biopolymer backbone to enable high drug-antibody-ratio ('DAR') medicines. The diverse APIs are designed to be released over time to achieve targeted, multi-specific and tailored modulation of biological pathways.

Kodiak正在推进其平台技术，将小分子和其他活性药物成分（“API”）嵌入Kodiak专有的生物聚合物骨架中，以实现高药物抗体比（“DAR”）药物。这些多样化的API旨在随着时间的推移释放，以实现对生物通路的靶向、多特异性和定制调节。

The unique combination of high DAR and tailored therapeutic benefit offers potential for broad application to multifactorial diseases and builds directly from our Antibody Biopolymer Conjugate technology and its 15 years of design, development and manufacturing experience. We call this platform extension our Antibody Biopolymer Conjugate Drug ('ABCD') Platform because we are extending our platform capabilities to include the conjugation of small molecule drugs and other APIs whereas historically, we primarily conjugated biologics such as antibodies. .

高DAR值的独特组合与定制的治疗效益为多因素疾病提供了广泛的应用潜力，并直接基于我们抗体生物聚合物偶联技术及其15年的设计、开发和制造经验。我们将这一平台扩展称为抗体生物聚合物偶联药物（“ABCD”）平台，因为我们正在扩展平台能力，以包括小分子药物和其他活性药物成分（API）的偶联，而历史上我们主要偶联的是如抗体等生物制品。

For more information, please visit

欲了解更多信息，请访问

www.kodiak.com

www.kodiak.com

.

。

Kodiak

科迪亚克

®

®

, Kodiak Sciences

，科迪亚克科学公司

®

®

, ABC

，ABC

®

®

, ABC Platform

，ABC平台

®

®

, ABCD™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions

，ABCD™ 和 Kodiak 标志是 Kodiak Sciences Inc. 在全球多个司法管辖区的注册商标或商标。

Forward-Looking Statements

前瞻性声明

This release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: the power and versatility of Kodiak's ABC.

本发布包含1933年《证券法》第27A条、1934年《证券交易法》第21E条以及1995年《私人证券诉讼改革法》所指的“前瞻性声明”。这些前瞻性声明并非基于历史事实，包括有关Kodiak的ABC的功能和多样性的声明。

®

®

platform; the enhanced therapeutic potential of KSI-102 for inflammatory ocular diseases; the potential of KSI-101 for the treatment of MESI; the potential for Kodiak's ABCD platform to enable the design and development of multifunctional, high DAR therapeutics for ophthalmic and systemic applications; and the optimization and further development of biopolymer conjugated therapeutic candidates with Kodiak's ABCD platform.

平台；KSI-102在治疗炎症性眼部疾病方面的增强治疗潜力；KSI-101在治疗MESI方面的潜力；Kodiak的ABCD平台在设计和开发用于眼科和系统应用的多功能、高DAR治疗药物方面的潜力；以及利用Kodiak的ABCD平台优化和进一步开发生物聚合物结合的治疗候选药物。

Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'could,' 'expect,' 'plan,' 'believe,' 'intend,' 'pursue,' and other similar expressions among others.

前瞻性声明一般包括具有预测性质的声明，这些声明取决于或涉及未来事件或条件，其中包括“可能”、“将”、“应该”、“会”、“能够”、“预期”、“计划”、“相信”、“意图”、“追求”以及其他类似表述。

Any forward-looking statements are based on management's current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially and adversely from those in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that cessation, modification or delay of any of the ongoing clinical studies may occur; the risk that our research and development efforts and our ability to advance our product candidates into later stages of development may fail; the risk that any one or more of our product candidates may not be successfully developed, approved or commercialized; the risk that adverse economic conditions may significantly impact our business and operations, including our clinical trial sites, and those of our manufacturers, contract research organizations or others with whom we conduct business; the risk that sufficient capital may not be available as expected, or at all, to complete the development of any products; as well as the othe.

任何前瞻性陈述均基于管理层对未来事件的当前预期，并受风险和不确定性的影响，这些风险和不确定性可能导致实际结果与此类前瞻性陈述中明示或暗示的结果存在重大且不利的差异。这些风险和不确定性包括但不限于：正在进行的临床研究可能发生终止、修改或延迟的风险；我们的研发工作以及将候选产品推进到开发后期的能力可能失败的风险；我们的一个或多个候选产品可能无法成功开发、获批或商业化的风险；不利的经济条件可能对我们的业务和运营（包括我们的临床试验地点以及我们的制造商、合同研究组织或其他与我们有业务往来的实体）产生重大影响的风险；可能无法按预期或根本无法获得足够资金以完成任何产品开发的风险；以及其他风险。

SOURCE Kodiak Sciences Inc.

来源：Kodiak Sciences Inc.

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

是否在PRNEWSWIRE.COM上展示？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用